Biomedicines
Polypharmacy and Drug-Drug Interaction Architecture in Hospitalized Cardiovascular Patients: Insights from Real-World Analysis.
Andrei-Flavius Radu, Ada Radu, Gabriela S Bungau, Delia Mirela Tit, Cosmin Mihai Vesa, Tunde Jurca, Diana Uivarosan, Daniela Gitea, Roxana Brata, Cristiana Bustea
Published: 202610.3390/biomedicines14010218
Abstract
Background: Cardiovascular polypharmacy inherently amplifies the risk of drug-drug interactions (DDIs), yet most studies remain limited to isolated drug pairs or predefined high-risk classes, without mapping the systemic architecture through which in…
Preview only. Read the full abstract at the source